(AQST) Aquestive Therapeutics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AQST) Aquestive Therapeutics, Inc. Complete Analysis Pack
Go Beyond the Preview—Access the Full Reference Sources
This Aquestive Therapeutics, Inc. SWOT Analysis summarizes the company’s core products (transdermal, oral film, and specialty CNS therapies), their uses, and a structured review of strengths, weaknesses, opportunities, and threats—shown here as a real preview of the product. The page includes a genuine sample so you can assess style and substance; purchase the full version to download the complete, ready-to-use SWOT report.
Strengths
4 commercialized products
Aquestive Therapeutics has 4 commercialized products: Sympazan, Suboxone, Zuplenz, and Azstarys. That gives it revenue-linked exposure across epilepsy, opioid dependence, nausea and vomiting, and ADHD. A broader base reduces dependence on one product and helps spread commercial risk.
Oral, sublingual, and buccal film expertise
Aquestive Therapeutics, Inc. is built on proprietary film-based drug delivery, with oral soluble, sublingual, and buccal films at the core of its model. That format can improve convenience and adherence for patients who struggle with tablets or capsules, especially in fast-use or swallowing-difficulty settings. It also gives Company Name a differentiated platform for reformulating drugs into patient-friendly doses.
7 named products and candidates
Aquestive Therapeutics, Inc. shows strength in 7 named programs across marketed products, pipeline assets, and prior work, including Libervant, Exservan, AQST-108, AQST-305, AQST-109, and KYNMOBI. That breadth points to repeatable formulation and development skill, not a one-off asset. It also gives the company more shots at approvals and revenue across multiple 2025-2026 programs.
Focus on unmet medical needs
Aquestive Therapeutics, Inc. focuses on unmet needs in seizures, ALS, acromegaly, and severe allergic reactions, where current treatment options can be slow, invasive, or hard to use. That target mix can support clinical relevance and stronger pricing power if products win approval and adoption. It also keeps the pipeline aimed at high-need specialty markets.
- Targets clear treatment gaps
- Fits specialty, high-value markets
- Supports pricing if adopted
U.S. and international market presence
Aquestive Therapeutics operates in the U.S. and international markets, so it is not tied to one demand pool. That reach can widen the addressable market for launches like Anaphylm and support country-by-country partnerships, which lowers dependence on a single channel. It also gives the Company more room to time launches where reimbursement and regulatory timing are strongest.
- Broader launch runway.
- More partner options.
- Less single-market risk.
Aquestive's 4 Products and 7 Programs Power 2025-2026 Growth
Aquestive Therapeutics has 4 commercialized products and 7 named programs, so it has more than one revenue and pipeline path. Its film-based oral, sublingual, and buccal delivery platform supports 2025-2026 launches in high-need areas like epilepsy, opioid dependence, ADHD, and anaphylaxis.
| Strength | Data |
|---|---|
| Commercial products | 4 |
| Named programs | 7 |
| Delivery platform | Film-based |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Aquestive Therapeutics, Inc.’s business strategy
Editable Excel File
Delivers a quick SWOT snapshot for Aquestive Therapeutics, Inc. to simplify strategic decision-making.
Reference Sources
Provides a concise bibliography of primary industry reports, FDA filings, and financial statements to speed due diligence and verify key claims about Aquestive Therapeutics.
Weaknesses
Only 4 commercial products
Aquestive Therapeutics, Inc. still relies on only 4 commercial products, so its marketed base is narrow. That makes total revenue more exposed to one product’s sales, pricing, or launch timing. It also leaves the Company with fewer steady cash-generating assets than larger peers, which can keep funding pressure high if one product underperforms.
Pipeline-heavy profile
Aquestive Therapeutics, Inc. is still a pipeline-heavy story: 5 key assets—Libervant, Exservan, AQST-108, AQST-305, and AQST-109—remain in development, so value still hinges on trial, FDA, and launch execution. Until approvals land, pipeline risk stays high, and any delay can push cash burn and revenue timing. That makes 2025-2026 milestones the main driver of upside, not current earnings.
Specialty indications only
Aquestive Therapeutics, Inc. leans on specialty-only targets like Lennox-Gastaut syndrome, ALS, and acromegaly, each with small patient pools; for example, ALS affects about 5 per 100,000 people, while acromegaly is roughly 60 per 1 million. That limits peak sales versus mass-market drugs, so growth depends on several niche wins, not one blockbuster.
Dependence on novel dosage forms
Aquestive Therapeutics, Inc.'s film-based dosing is a clear edge, but it also makes execution harder because each product needs tight control of thickness, drug load, and release. Regulators will test bioavailability, consistency, and usability closely, with bioequivalence often judged against the 80%-125% range, so even small batch drift can delay approval or launch.
- Film dosing adds manufacturing complexity.
- Regulators focus on bioavailability and consistency.
- Small production issues can slow adoption.
History since 2004 without scale leadership
Founded in 2004, Aquestive Therapeutics, Inc. still operates as a small pharma player more than 20 years later, so its long runway has not yet translated into scale leadership. That gap points to a slow commercial build and tighter resources than bigger rivals. In sales, marketing, and capital access, larger drug makers usually have a clear edge.
- Founded in 2004; still not scale-leading
- More than 20 years to build size
- Faces weaker reach than big pharma
Few Products, Narrow Markets, and Big Approval Risk
Aquestive Therapeutics, Inc. has a thin base: only 4 commercial products, while 5 key assets are still in development, so 2025-2026 value still depends on approvals and launches. Its niche focus also caps scale: ALS affects about 5 per 100,000 people and acromegaly about 60 per 1 million. Film dosing adds manufacturing risk, and its small size limits sales reach and cash power.
| Weakness | Data point |
|---|---|
| Commercial base | 4 products |
| Pipeline risk | 5 key assets |
| ALS prevalence | 5 per 100,000 |
Full Version Awaits
Aquestive Therapeutics, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it summarizes Aquestive Therapeutics' strengths, weaknesses, opportunities, and threats with actionable insights.
Opportunities
Libervant seizure treatment
Libervant is Aquestive Therapeutics, Inc.'s diazepam buccal soluble film for seizure treatment, aimed at a real acute-care gap in epilepsy. The U.S. has about 3.4 million people with epilepsy, and a non-oral option can help patients who cannot swallow during a seizure. If uptake grows, Libervant could add a differentiated, convenient rescue option in a market where speed and ease of use matter most.
AQST-109 oral epinephrine
AQST-109 is Aquestive Therapeutics, Inc.'s oral epinephrine program for anaphylaxis, a market where fast use matters and current auto-injectors still face training, timing, and needle barriers.
The U.S. sees about 1 in 50 people affected by food allergy, and anaphylaxis remains a recurring emergency, so an oral option could widen real-world use and improve access.
If approved, AQST-109 could create a new epinephrine category and add a large commercial lane beyond the current device-led market.
AQST-108 systemic epinephrine
AQST-108, a sublingual epinephrine film, could open a new growth lane beyond anaphylaxis and expand Aquestive Therapeutics, Inc.’s reach into other systemic uses. That matters because the platform is already commercialized, so one delivery system could support more than one therapy. If approved in additional indications, it could add revenue without starting from zero.
AQST-305 acromegaly treatment
AQST-305 is a sublingual octreotide film for acromegaly, a rare disease affecting about 60 people per 1 million. That small pool can support specialty pricing and focused sales, especially with 7-year U.S. orphan exclusivity.
If Aquestive Therapeutics, Inc. wins launch traction, AQST-305 could expand revenue beyond its current core oral and rescue products and add a higher-value endocrine franchise.
- Rare-disease pricing supports margins
- Focused launch lowers commercial waste
- Success broadens Aquestive Therapeutics, Inc.
International expansion of film products
Aquestive Therapeutics, Inc. already sells in U.S. and international markets, so it can push existing film products into new geographies without building a new platform. That can lift revenue faster through local partners and regulatory wins, especially if international approvals mirror U.S. demand for thin-strip therapies.
- Uses current products, not new R&D
- Adds revenue with partner deals
- Scales faster after approvals
Aquestive’s Film Platform Targets Big, Underserved Markets
Opportunities for Aquestive Therapeutics, Inc. center on turning its film platform into multiple products: Libervant, AQST-109, AQST-108, and AQST-305. With 3.4 million U.S. epilepsy patients, about 1 in 50 people affected by food allergy, and acromegaly at roughly 60 per 1 million, the addressable need is real. A wider label and new geographies could add revenue without rebuilding the core platform.
| Area | Key data |
|---|---|
| Epilepsy | 3.4M U.S. patients |
| Food allergy | 1 in 50 people |
| Acromegaly | 60 per 1M |
Threats
Regulatory approval risk
Regulatory approval risk is high because Aquestive Therapeutics, Inc.’s pipeline still depends on clinical success and FDA review. For oral epinephrine, any request for more data, label limits, or non-approval could push back revenue and keep cash burn elevated. That matters even more for first-in-category drugs, where the approval bar is higher and timelines can slip fast.
Competition from established therapies
Aquestive Therapeutics, Inc. faces entrenched branded and generic rivals in epilepsy, nausea, opioid dependence, ADHD, Parkinson’s, and allergy care. With generics filling about 90% of U.S. prescriptions, prescribers often stick to familiar, lower-cost options. Switching costs, prior auth, and formulary hurdles can slow uptake and cap share gains.
Generic and pricing pressure
Generic and pricing pressure remains a key threat for Aquestive Therapeutics, Inc. Suboxone Film has faced generic competition since 2019, and mature oral and transmucosal products often see lower net pricing as payers push rebates and reimbursement cuts. Even if volume holds, weaker net price can still compress gross margin and cash flow.
Clinical development failure
Clinical development failure is a major threat for Aquestive Therapeutics, Inc. because its growth depends on a small set of pipeline programs. If one key candidate slips in testing or review, the Company can lose a large part of its future revenue upside. That risk is sharper for small biotechs, where one setback can move valuation fast.
- Few pipeline shots drive growth
- One failure cuts upside fast
- Small caps feel pipeline risk more
Manufacturing and access challenges
Manufacturing is a real threat for Aquestive Therapeutics, Inc. because its film formulations need tight production controls and steady supply, so any batch issue or delay can hit output fast. Novel dosage forms can also face slower payer coverage and pharmacy adoption, which can delay patient starts and weaken sales momentum.
- Specialized film production raises supply risk.
- Payer coverage can slow pharmacy access.
- Any disruption can stall commercial growth.
For a company built on new delivery forms, even a short manufacturing or reimbursement break can push revenue timing back.
FDA Risk and Generic Pressure Keep Aquestive’s Growth Under Pressure
Aquestive Therapeutics, Inc. still faces high FDA and clinical risk: one setback on oral epinephrine or any lead program can delay revenue and lift cash burn. Generic pressure is also tough, with about 90% of U.S. prescriptions filled by generics, so pricing and access can stay weak. Manufacturing and payer hurdles can slow starts and stall growth.
| Threat | Key data |
|---|---|
| Generic pressure | ~90% U.S. Rx are generics |
| Suboxone Film | Generic competition since 2019 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.